Actively Recruiting
Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board
Led by H. Lee Moffitt Cancer Center and Research Institute · Updated on 2026-04-01
35
Participants Needed
1
Research Sites
408 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will evaluate the ability of a multidisciplinary group, the Evolutionary Tumor Board (ETB), to develop therapeutic strategies in patients without curative options.
CONDITIONS
Official Title
Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participant must be considered likely incurable given a standard of care, including remission with high risk of recurrence or suboptimal response to previous therapy
- Participant must have a life expectancy greater than 3 months
- Participant must have an ECOG performance status of 0 to 2
- Participant and primary oncologist must be willing to consider therapeutic strategies recommended by the Evolutionary Tumor Board
- Willingness to be followed over time with collection of clinical data including scans and serial blood sampling
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Moffitt Cancer Center
Tampa, Florida, United States, 33613
Actively Recruiting
Research Team
S
Sara Donadelli
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here